Cargando…
Identification of nuclear export inhibitor-based combination therapies in preclinical models of triple-negative breast cancer
An estimated 284,000 Americans will be diagnosed with breast cancer in 2021. Of these individuals, 15–20% have basal-like triple-negative breast cancer (TNBC), which is known to be highly metastatic. Chemotherapy is standard of care for TNBC patients, but chemoresistance is a common clinical problem...
Autores principales: | Rashid, Narmeen S., Hairr, Nicole S., Murray, Graeme, Olex, Amy L., Leftwich, Tess J., Grible, Jacqueline M., Reed, Jason, Dozmorov, Mikhail G., Harrell, J. Chuck |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8512760/ https://www.ncbi.nlm.nih.gov/pubmed/34628286 http://dx.doi.org/10.1016/j.tranon.2021.101235 |
Ejemplares similares
-
Transcriptomic changes underlying EGFR inhibitor resistance in human and mouse models of basal-like breast cancer
por: Rashid, Narmeen S., et al.
Publicado: (2022) -
Stratification of Tamoxifen Synergistic Combinations for the Treatment of ER+ Breast Cancer
por: Zboril, Emily K., et al.
Publicado: (2023) -
Discovering Synergistic Compounds with BYL-719 in PI3K Overactivated Basal-like PDXs
por: Boyd, David C., et al.
Publicado: (2023) -
Rewiring of the 3D genome during acquisition of carboplatin resistance in a triple-negative breast cancer patient-derived xenograft
por: Dozmorov, Mikhail G., et al.
Publicado: (2023) -
Publisher Correction: Rewiring of the 3D genome during acquisition of carboplatin resistance in a triple-negative breast cancer patient-derived xenograft
por: Dozmorov, Mikhail G., et al.
Publicado: (2023)